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We examined perioperative complications of transurethral resection of bladder tumor (TURBT) in
patients receiving antithrombotic therapy. We retrospectively studied 276 patients who underwent TURBT
in our institute from January 2007 to March 2013. The study group consisted of 105 patients (38%) who
were receiving antithrombotic agents, and the other 171 patients (62%) without antithrombotic agents were
assigned to the control group. The period of discontinuation of antithrombotic agents complied with our
institutional rule. The most frequently used agent was aspirin (69 patients : 66%), followed by warfarin (25
patients : 24%). Fourteen patients receiving warfarin (56%) needed heparin bridging therapy. There was
no signiﬁcant difference in average operative time (51 minutes versus 54 minutes), or average days to removal
of urethral catheter (3.7 days versus 3.3 days) between the study and control groups. Hemorrhagic and
ischemic complications were noted in 11 (10.5%) and 2 (1.9%) patients in the study group and 11 (6.4%) and
none (0%) of the patients in the control group, respectively, with no signiﬁcant difference between the 2
groups. However, prevalence of hemorrhagic complications in patients receiving heparin bridging therapy
(21.4%) was signiﬁcantly higher than that in the control group. Ischemic complications in the study group
included chest pain suggestive of angina in one patient and acute myocardial infarction leading to death in
another patient. We should pay attention to hemorrhagic complications in patients receiving heparin
bridging therapy and keep in mind the possibility of lethal ischemic complications after discontinuation of
antithrombotic agents.
(Hinyokika Kiyo 60 : 531-535, 2014)
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Table 1. Details of antithrombotic
Anticoagulant 26 (25％)
Warfarin 25 (24％)
Rivaroxaban (Xarelto○R ) 1 ( 1％)
Heparin bridging 14 (56％)
Antiplatelet 74 (70％)
Aspirin 69 (66％)
Cilostazol (Pletaal○R ) 15 (14％)
Ticlopidine (Panaldine○R ) 13 (12％)
Beraprost (Procylin○R/Dorner○R ) 7 ( 7％)
Ifenprodil (Cerocral○R ) 6 ( 6％)
Limaprost alfadex(Opalmon○R ) 5 ( 5％)
Clopidogrel (Plavix○R ) 4 ( 4％)
Icosapentate (Epadel○R ) 4 ( 4％)
Sarpogrelate (Anplag○R ) 3 ( 3％)
Table 2. Characteristics of study and control patients
Study group Heparin bridging (＋) Heparin bridging (−) Control group
No of patients 105 14 91 171
Age (yrs) 75±12 72±12 76±12 73±11
M/F ratio 92 : 13 (M : 88％)* 11 : 3 (M : 79％) 81 : 10 (M : 89％)* 130 : 41 (M : 76％)
Surgical time (min) 51±32 43±21 52±33 54±45
Immediate intravesical instillation of MMC
n (％) 43 (41％) 4 (29％) 39 (43％) 65 (38％)
Foley withdrawal (POD) 3.7±2.1 4.1±2.1 3.7±2.1 3.3±2.6


























































を Table 2 に示す．年齢，手術時間，MMC 施行例お
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Fig. 1. Number of patients receiving antithrombotic according to age and sex.
Table 3. Comparison of perioperative complications between study and control groups
Study group Heparin bridging (＋) Heparin bridging (−) Control group
No of patients 105 14 91 171
Bleeding complications 11 (10.5％) 3 (21.4％)* 8 (8.8％) 11 (6.4％)
Catheter obstruction/bladder irri-
gation 9 (8.6％) 3 (21.4％)* 6 (6.6％) 8 (4.7％)
Blood transfusion 1 (1.0％) ― 1 (1.1％) ―
Transurethral coagulation 1 (1.0％) ― 1 (1.1％) 3 (1.8％)
Ischemic complications 2 (1.9％) ― 2 (2.2％) ―
Bladder perforation 3 (2.9％) ― 3 (3.3％) 3 (1.8％)
Open repair surgery 1 (1.0％) ― 1 (1.1％) ―
Infection/fever 4 (3.8％) 1 (7％) 3 (3.3％) 1 (0.6％)
Parenteral antibiotic 2 (1.9％) 1 (7％) 1 (1.1％) 1 (0.6％)
Others ― ― ― 3(1.8％)
Af Headache Hypotention
Total 20 (19.0％)* 4 (28.6％) 16 (17.6％) 18 (10.5％)
* P＜0.05 vs Control patients.
よび尿道留置カテーテル抜去時期はどの群間において
も有意差を認めなかった．対象群で男性が有意に多
































































































































続による risk と beneﬁt の適切なバランスをとること
ができるように，日本人を対象とした周術期の抗血栓
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